Abstract. Yellow fever (YF) is a significant health problem in South America and Africa. Travelers to these areas require immunization. The United States, infested with Aedes aegypti mosquitoes, is at risk of introduction of this disease. There is only a single U.S. manufacturer of YF 17D vaccine, and supplies may be insufficient in an emergency. A randomized, double-blind outpatient study was conducted in 1,440 healthy individuals, half of whom received the U.S. vaccine (YF-VAX) and half the vaccine manufactured in the United Kingdom (ARILVAX). A randomly selected subset of approximately 310 individuals in each treatment group was tested for YF neutralizing antibodies 30 days after vaccination. The primary efficacy endpoint was the proportion of individuals who developed a log neutralization index (LNI) of 0.7 or higher. Seroconversion occurred in 98.6% of individuals in the ARILVAX group and 99.3% of those in the YF-VAX group. Statistically, ARILVAX was equivalent to YF-VAX (P ‫ס‬ .001). Both vaccines elicited mean antibody responses well above the minimal level (LNI 0.7) protective against wild-type YF virus. The mean LNI in the YF-VAX group was higher (2.21) than in the ARILVAX group (2.06; P ‫ס‬ .010) possibly because of the higher dose contained in YF-VAX. Male gender, Caucasian race, and smoking were associated with higher antibody responses. Both vaccines were well tolerated. Overall, the treatment groups were comparable with respect to safety except that individuals in the ARILVAX group experienced significantly less edema, inflammation, and pain at the injection site than those in the YF-VAX group. No serious adverse events were attributable to either vaccine. YF-VAX participants (71.9%) experienced one or more nonserious adverse events than ARILVAX individuals (65.3%; P ‫ס‬ .008). The difference was due to a higher rate of injection site reactions in the YF-VAX group. Mild systemic reactions (headache, myalgia, malaise, asthenia) occurred in roughly 10% to 30% of participants during the first few days after vaccination, with no significant difference across treatment groups. Adverse events were less frequent in individuals with preexisting immunity to YF, indicating a relationship to virus replication.
INTRODUCTION
Yellow fever (YF) is a severe mosquito-borne hemorrhagic fever characterized by hepatitis, renal failure, bleeding, and shock. The etiologic agent is the prototype of the Flaviviridae family of single-strand RNA viruses that includes dengue and West Nile viruses. YF is endemic/epidemic in tropical South America and Africa, where up to 200,000 cases occur annually. 1, 2 Four deaths occurred recently in unvaccinated tourists from the United States and Europe. The high case-fatality rate (20-50%) makes YF one of the most dreaded infectious diseases.
A safe, effective vaccine against YF, the 17D strain, was originally developed by Theiler and Smith (cited in Monath 3 ) in 1936 by attenuating the wild-type Asibi strain in mouse and chick tissue. YF vaccines are manufactured by inoculation of 17D virus seed into chicken embryos and harvesting the infected embryos under standards developed by World Health Organization (WHO). The molecular basis for attenuation, biological, and antigenic attributes and usage as a vaccine for prevention and control of YF are described elsewhere. 3 After subcutaneous inoculation of YF vaccine, neutralizing antibodies appear by Day 10 after inoculation, and immunity is probably lifelong, 4 although revaccination is recommended every 10 years. In spite of increasing demands for vaccine, the number of manufacturers has decreased from 13 in 1980 to 8 in 2000. In the United States, there is a single manufacturer (Aventis-Pasteur, Swiftwater, PA) producing approximately 700,000 doses annually.
The United States is vulnerable to the introduction of YF by travelers from endemic countries. Large areas of the southern United States are infested with the vector mosquito Aedes aegypti. The recent introductions of other flaviviruses, West Nile and dengue, illustrate the potential for outbreaks of exotic mosquito-borne diseases. The availability of a single vaccine limits the nation's capability to respond to epidemic YF.
Here we describe a Phase 3 clinical trial of a YF 17D vaccine (ARILVAX) licensed in the United Kingdom and certain other countries. The principal objective was to compare the safety and efficacy of ARILVAX to the vaccine licensed in the United States (YF-VAX).
METHODS

Vaccines.
The history of derivation of YF 17D vaccine has been reviewed elsewhere. 3 ARILVAX and YF-VAX are derived from a common ancestor in the passage series following derivation of original 17D vaccine, designated Colombia No. 88 (passage 228). A small number of independent passages in eggs were made at the Rockefeller Foundation or the Rocky Mountain Laboratory (National Institutes of Health) before the manufacture of primary seed stocks in the United Kingdom and the United States. The passage lineage and origin of the vaccines produced in the United Kingdom and the United States is shown in Figure 1 . A seed lot system for control of passage level of YF 17D vaccines was introduced by all manufacturers by 1945 or earlier, ensuring that vaccine lots for human vaccines are not more than a single passage from a well-characterized secondary (working) seed.
ARILVAX and YF-VAX are produced in chicken eggs that are obtained from pathogen-free flocks. The seed virus is inoculated into approximately 7-to 9-day-old embryonated eggs. After a 3-to 4-day incubation, infected embryos are aseptically harvested, homogenized, and clarified by centrifugation to produce bulk vaccine. The bulk vaccine is diluted, stabilizers are added, and the vaccine is filled into vials and freeze dried. As specified by WHO standards, potency per 0.5-mL dose exceeds 1,000 mouse 50% lethal doses (MLD 50 ) or the equivalent in cell culture plaque titer. The dose in the final container exceeds the minimum specification by at least fivefold to account for potential losses during storage.
Manufacture of YF 17D vaccine in the United Kingdom according to WHO specifications commenced in 1945 at the Wellcome Research Laboratories. In 1965 an avian leukosisfree vaccine was introduced, and in 1976 the vaccine was improved by the addition of stabilizers. ARILVAX (Evans Vaccines, Speke, Liverpool, UK) is supplied as a freeze-dried powder. When reconstituted with water for injection, it contains not less than 4.4 log 10 plaque-forming units (PFUs) of YF 17D virus per 0.5-mL dose. In addition to the vaccine, each vial contains sorbitol and hydrolyzed porcine gelatin as stabilizers, sodium chloride, disodium hydrogen orthophosphate, potassium chloride, and potassium dihydrogen orthophosphate. The vaccine is given as a single subcutaneous inoculation in the deltoid region.
In the United States, production of YF 17D vaccine began in research laboratories at the Rockefeller Foundation in New York in 1937. Beginning in 1941, the vaccine was produced by the U.S. Public Health Service, Rocky Mountain Laboratories. In 1952, manufacture was transferred to the National Drug Co (Swiftwater, PA), which has since changed control a number of times (National Drug Co., Connaught Laboratories, and Pasteur-Merieux Connaught, now known as Aventis-Pasteur). In 1969, a stabilized, leucosis-free formulation was introduced. The origin and passage history of YF-VAX with respect to the original 17D strain and ARILVAX are shown in Figure 1 . YF-VAX is a freeze-dried powder containing sorbitol and hydrolyzed porcine gelatin stabilizers. When reconstituted with 0.9% sodium chloride, it contains not less than 5.04 log 10 PFU of YF 17D virus per 0.5-mL dose. The method of administration is the same as for ARILVAX.
The nucleotide sequence of the complete genome of the seed virus used to manufacture ARILVAX is reported elsewhere and compared with YF-VAX. 5 Briefly, The ARILVAX sequence differs from the published sequence of YF-VAX at 15 nucleotide residues. With the exception of two nucleotides (nt 4054 and 10454), these differences are heterogeneities, each containing a nucleotide present in YF-VAX accompanied by an additional nucleotide in the ARILVAX virus population. Only two of the changes result in amino acid differences: one at amino acid 240 in the envelope (E) gene (YF-VAX alanine; ARILVAX mixture of alanine and valine) and one at position 195 in NS3 (YF-VAX valine; ARILVAX valine and isoleucine). The methodology used for original sequencing of YF-VAX may not have revealed existing heterogeneities at these positions.
Trial design. The study was conducted in healthy adults older than 18 years at nine centers in the United States. Equal numbers of individuals were assigned to receive ARILVAX or YF-VAX using stratified randomization by gender, race, and study site. Individuals were excluded who had significant medical conditions; contraindications to YF vaccine (pregnancy, immunosuppression, egg hypersensitivity); positive tests for hepatitis B surface antigen (HBsAg) or hepatitis C or HIV antibody; previous vaccination with YF or another flavivirus; or travel to a YF endemic area.
On Day 1, participants received one of the two vaccines. They were interviewed by telephone on Day 5 and returned to the clinic on Days 11 and 31. Participants completed a symptom diary from Day 1 through Day 10. Scripted questions were used during interviews to prompt reporting of injection site and systemic reactions. Clinical laboratory evaluations were performed during screening and on Day 11.
Antibody tests. Neutralizing antibodies to YF were measured by a constant serum-varying virus plaque-reduction test technique standardized by the Bureau of Biologics, Food and Drug Administration. 6 Seroconversion was defined as a log 10 neutralization index (LNI) of 0.7 or higher. The LNI test was validated and performed according to Good Manufacturing Practices at Acambis Inc. The LNI is the log 10 difference in virus titer of a mixture of serum and virus between the Day 1 and Day 31 samples. The cutoff for a positive LNI was 0.7. 7, 8 To identify individuals who were YF seropositive and seronegative at baseline, the prevaccination Day 1 serum sample was tested against a negative serum control. The Day 1 sample was also tested for the presence of hemagglutination-inhibiting (HI) antibodies to heterologous flaviviruses (St. Louis encephalitis, dengue-2, Ilheus, and West Nile).
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Statistical methods. Sample size and power. The sample size for safety establishes an upper bound of 0.004 for the 95% confidence interval (CI) for the incidence of an adverse event in the case that the event is not observed among the 720 individuals in either the ARILVAX or YF-VAX treatment groups. A sample size for efficacy of 200 to 225 individuals per group provides 90% power in a one-sided test of noninferiority at significance level alpha of 0.05 when the overall seroconversion rate is assumed to be 97% and the response rate in the test population varies between 90% and 99%.
Primary endpoint. The goal of the study was to show equivalence by a test of noninferiority of ARILVAX to YF-VAX. ARILVAX is considered noninferior to YF-VAX if the seroconversion rate for ARILVAX is not lower than the seroconversion rate for YF-VAX by more than a clinically acceptable difference of 5%. A 50% sample of each treatment group was randomly selected for serological testing based on power calculations for the sample size required to show equivalence of the two vaccines. Individuals who were seropositive on Day 1 were subsequently excluded from the analysis. The difference in seroconversion rates, the upper one-sided CI, and the P-value for the test that the difference in serocoversion rates is larger than 5% were calculated. The P-value was computed using the exact test of equivalence for two binomials. 10 Secondary endpoint. The secondary endpoint was the LNI at the Day 31 visit. Treatment groups were compared by analysis of variance (ANOVA).
Supplemental endpoints: effect of host factors. Supplemental analyses addressed the role of host factors in the immune response (mean LNI); treatment groups were compared after adjusting for each factor. The overall impact of host factors on the LNI was then investigated in a multifactor regression model, which included treatment, gender, race group, smoking, and military service.
Safety assessments. Adverse events (AEs) were summarized by and within body system; each participant was counted once for each body system and once for each AE within each body system. P-values for differences between treatment groups were determined by chi-square or Fisher's exact test. Causality was estimated by the principal investigator at each site based on temporal relationship of AEs to administration of study medication, the existence of signs and symptoms indicating alternative diagnoses, and clinical judgment. "Drug-related" AEs were those considered remotely, possibly, probably, or definitely related to clinical trial materials.
All AEs were analyzed for three study periods (Days 1-5, Days 1-11, and Days 1-31). Kaplan-Meier survival curves were used to depict the time-to-event distribution for each of the two treatments; treatment groups were compared by logrank test.
RESULTS
Number of participants.
A total of 715 individuals received ARILVAX and 725 received YF-VAX. We randomly selected 308 ARILVAX and 312 YF-VAX subjects for serological testing, of which 283 (91.9%) and 291 (93.3%), respectively, were efficacy evaluable (seronegative at baseline and Paired Days 1 and 31 sera tested).
Demographic and baseline characteristics. Treatment groups were well balanced with respect to baseline characteristics. In both groups, the mean age was approximately 38 years, roughly 60% of participants were female, and about 80% were Caucasian. The safety-evaluable populations differed in racial distribution (P ‫ס‬ .016) because of a higher number of Asian individuals in the YF-VAX group (2.3% vs. 0.3%, respectively).
Efficacy. Seroconversion occurred in 98.6% of individuals in the ARILVAX group and 99.3% of individuals in the YF-VAX group (Table 1 ). The one-sided test of noninferiority showed that ARILVAX was not inferior to YF-VAX (P ‫ס‬ .001; the difference in seroconversion was 0.7% with an upper one-sided 95% CI of 4.3%).
The secondary endpoint was a comparison of treatment groups for mean LNI at Day 31. The mean LNI was 2.06 and 2.21 for the ARILVAX and YF-VAX groups (Table 2) . Although small, the difference of 0.15 between treatment groups was statistically significant (P ‫ס‬ .010). Both vaccines elicited mean antibody responses well above the level (LNI Ն 0.7) protective against natural exposure to wild-type YF virus. 7 The difference between the treatment groups was not due to a skewed distribution, and there was no clustering of ARILVAX LNI values at the low end of the range (Figure 2) .
Effect of host factors on the neutralizing antibody response. Gender. The antibody response was significantly higher in males in both treatment groups (P ‫ס‬ .001, ANOVA; Table 3 ). The mean LNI in the YF-VAX treatment group remained significantly higher after adjustment for gender (P ‫ס‬ .008, ANOVA). In a backward elimination regres- sion model that considered interaction of multiple host factors, gender was nearly significant (P ‫ס‬ .053).
Race. Hispanic and African American individuals had lower mean LNI values than those in the "Other" category regardless of treatment group (P ‫ס‬ .017, ANOVA) ( Table 4) . When adjusted for race group alone, no significant difference in the mean LNI was observed between treatment groups. However, in the backward elimination regression model that considered interaction of multiple factors, both race group and treatment remained significant factors.
Smoking. Fifty-four (19%) and 73 (25%) individuals in the ARILVAX and YF-VAX groups were smokers. In these groups, respectively, the mean LNI was higher (2.26 and 2.27) in smokers than nonsmokers (2.01 and 2.19) (P ‫ס‬ .017, ANOVA). When adjusted for smoking status, there was no statistical difference between the mean LNI in the ARILVAX and YF-VAX treatment groups (P ‫ס‬ .188). In the backward elimination regression model, smoking was not a significant factor.
Military service history. The mean LNI in subjects with military service was higher than in those without military service in both treatment groups. However, in the backward elimination regression model, military service was not a significant factor. The small number of subjects (n ‫ס‬ 40) with military history precluded meaningful analysis.
Flavivirus HI antibody at baseline. At baseline, the prevalence of HI antibodies in the ARILVAX and YF-VAX groups was similar (2.1% and 1.7%, respectively). HI antibody was not a significant factor in influencing LNI (P ‫ס‬ .269, ANOVA). However, the numbers of flavivirus-immune individuals was too small to draw conclusions about the role of this covariate.
Age. There was no difference in the mean LNI between individuals younger than 40 years and those 40 years of age and older.
Safety. Three individuals in the ARILVAX treatment group experienced four serious adverse events: myocardial infarction (fatal); bacterial orbital cellulitis; worsening polycythemia vera; and femoropopliteal thrombophlebitis in the patient with polycythemia vera). These events were considered to be definitely not related or (in the case of orbital cellulitis) remotely related to vaccine. There were no serious adverse events in the YF-VAX group.
Significantly more individuals in the YF-VAX group (71.9%) experienced one or more nonserious, drug-related AEs than in the ARILVAX group (65.3%, P ‫ס‬ .008) ( Table  5) . The difference was due to a higher rate of local reactions in the YF-VAX group. Injection site reactions were of mild to moderate severity in nearly all cases. Four local reactions were considered severe, all in the YF-VAX group.
There were no differences between treatment groups in systemic AEs (see Table 5 ). The most common AEs were headache, asthenia, myalgia, malaise, fever, and chills. These were generally mild or moderate. In the ARILVAX and YF- VAX groups, respectively, 7.2% and 8.1% of all treatmentemergent AEs were severe (interfered with normal activities). Rash was noted at a similar frequency in the ARILVAX (2.9%) and YF-VAX (3.2%) treatment groups. There was one case of urticaria in the ARILVAX group (0.1%) and two cases in the YF-VAX group (0.3%). There were no cases of anaphylaxis, serum sickness, or other severe allergic reactions.
Relationship of adverse events and age. A total of 123 (8.5%) of 1,440 subjects were older than 60 years. None of the serious adverse events occurred in elderly participants. The incidence of nonserious AEs was lower in elderly persons than in younger individuals, and the difference was statistically significant for headache, malaise, injection site edema, and pain (Table 6) .
Temporal relationship of adverse events to vaccination. Injection site reactions occurred between Days 1 and 5 ( Figure  3 ). Systemic AEs also occurred at highest incidence during this interval but continued between Days 6 and 11. The survival distributions for YF-VAX local reactions were significantly different from the ARILVAX group (P < .001, logrank test), reflecting the higher incidence and faster occurrence of these events in the YF-VAX group.
Relationship between AEs and virus replication. Asthenia, malaise, headache, fever, injection site inflammation, and injection site pain occurred at a significantly lower rate (P < .05) or showed a trend toward occurring at a lower rate (P < .10) in individuals who were seropositive at baseline ( Table 7) , indicating that these reactions were associated with active replication of vaccine virus.
Clinical laboratory tests. The mean white blood cell count decreased slightly between baseline and Day 11, with a mild neutropenia (Table 8) . Because a large number of individuals were tested, small differences in mean values were statistically significant. No very low counts (below 2.0 × 10 3 /L) were observed. Platelet counts decreased slightly in both groups. No participants developed clinically significant thrombocytopenia (< 0.5 × 10 5 /L). In the ARILVAX and YF-VAX groups, 3.5% and 3.9%, respectively, had elevations in aspartate aminotransaminase (AST) and 3.9% and 4.6%, respectively, had an increase in alanine aminotransferase (ALT) from normal to abnormal range between baseline and Day 11. In most cases levels were minimally elevated and in no case did AST exceed 260 IU/mL or ALT 220 IU/mL. Among participants who were followed up, levels returned to normal or had decreased by Day 31. Individuals with elevated serum enzymes had no associated syndrome or constellation of other clinical laboratory abnormalities. There was no relationship between elevated serum enzymes and use of concomitant medications known to cause hepatic dysfunction.
DISCUSSION
This is the largest clinical trial of YF 17D vaccines ever conducted. 3 It confirmed that these vaccines are well tolerated and highly immunogenic. ARILVAX and YF-VAX elicited neutralizing antibodies in approximately 99% of individuals. ARILVAX had equivalent immunogenicity to YF-VAX (test of noninferiority, P ‫ס‬ .001).
It is not surprising that the two vaccines had similar characteristics. ARILVAX and YF-VAX are derived from the same virus strain, Colombia 88, representing the 228th passage from the original 17D. 11 The vaccines manufactured in the United Kingdom and United States since the 1940s differ by only 16 passages (see Figure 1) . The nucleotide sequence of ARILVAX differs from the United States vaccine 12 at only 15 of 10,862 nucleotides (0.14%), most of which are silent changes. Amino acid heterogeneity was detected at only two residues (see Methods and Pugachev and others 5 ). It is not possible to attribute the minor differences in immunogenicity and reactogenicity to genome differences between the vaccines. Differences in dose and the concentration of substrate (egg)-derived proteins could also be responsible for the clinical effects.
Neutralizing antibody is the principal mediator of protective immunity against YF. 3 The mean LNIs were 2.06 and 2.21 for ARILVAX and YF-VAX, respectively. The slightly lower response in the ARILVAX group might reflect the 4.4-fold lower dose of live virus in this formulation. The minimum antibody level protective against lethal challenge determined experimentally in monkeys was greater than 0.7.
7 Rhesus monkeys are significantly more susceptible than humans, 13, 14 however, so that the LNI cutoff for protective immunity in the monkey overestimates the titer required to protect humans. Only 1.4% of ARILVAX and 1.7% of YF-VAX individuals had low LNI values (0.7-1.05) (Figure 2 ). It is unlikely that the slightly lower mean LNI value for ARILVAX would affect durability of the antibody response to this vaccine. Others have shown that neutralizing antibodies persist for as long as the interval studied (10 to >35 years 4 ). The study revealed hitherto unknown effects of host factors on the antibody response. Males had significantly higher responses in both treatment groups. Naturally acquired YF disease is more frequent in males, a finding that cannot be explained by epidemiological factors. 3 Moreover, postvaccinal encephalitis caused by an early YF vaccine (French neurotropic) was higher in males than in females, suggesting that males undergo a more active infection.
The race group with predominantly Caucasians had a higher mean antibody response than African Americans and Hispanics. The lethality of wild-type YF appears to be lower in Africans Americans than Caucasians, but it is uncertain whether this is due to acquired immunity or genetic resistance. 3 In dengue, however, African Americans are at significantly lower risk of severe disease than Caucasians. 15 The lower immune responsiveness of African Americans in our study and the lower incidence of dengue hemorrhagic fever in African Americans may reflect a genetic difference in susceptibility to flavivirus replication.
Smoking may have modified the response to YF vaccine. There are few studies on the interaction of smoking and the immune system, but most report a suppressive effect. [16] [17] [18] [19] Smoking may depress natural killer (NK) cell function. 17, 20 It is possible that smoking-induced depressed NK cell function could enhance early replication of YF 17D vaccine and thus upregulate the adaptive immune response.
Dengue immunity diminished the response to YF vaccine in some studies. 21 The prevalence of heterologous flavivirus infection in the study population was too low and the number of flavivirus immune participants too small to determine any effect on the immune response to YF vaccine in this study.
Both ARILVAX and YF-VAX were well tolerated. The number of individuals in the trial was too small to reveal the extremely rare, serious adverse events associated with these vaccines, such as anaphylaxis, postvaccinal encephalitis, and multiple organ damage. Anaphylactic reactions to YF-VAX occur at an incidence of approximately 1/58,000. 22 In a postmarketing analysis, the incidence of significant multisystem and neurologic adverse events was 2.42 and 3.73/100,000 in the United States 23 and the United Kingdom (T. P. Monath and M. Cetron, unpublished data, 2000), respectively. The number of doses administered were 1.44 million and 0.96 million, respectively. The slightly higher incidence in the United Kingdom probably reflects higher reporting sensitivity. Fatal reactions have been extremely rare. Up to now, six fatal cases causally related to YF 17D vaccines have been reported, in- cluding a case of encephalitis 24 in a child in the United States, three cases with multisystem failure in elderly persons in the United States, 23 and two similar cases in a child and a young adult in Brazil. 25 The Brazilian cases had a clinicopathological picture resembling wild-type YF and occurred during a campaign in which 34 million doses were given. Most events appear to be due to an abnormal response of the individual host rather than to mutations in the vaccine virus. The occurrence of mild, transient subclinical elevations in serum transaminase enzymes in approximately 3.5% of individuals in both the ARILVAX and YF-VAX groups suggests that YF 17D may retain the ability to cause hepatic infection and injury. However, transaminase elevations are not uncommon in clinical trials; without a placebo group, it is not possible to determine causality of the hepatic dysfunction.
The current study provided new data on common side effects of YF 17D vaccines. Injection site reactions were reported by 8.5% to 24% of individuals in the ARILVAX group and 20% to 39% of those in the YF-VAX group. The local reactions had an objective component (redness, swelling) and occurred in close temporal relationship to vaccination ( Figure 3 ). The incidence of local reactions was lower in individuals with preexisting YF immunity than in those without (see Table 7 ), suggesting that the reactions were related to live virus replication at the site of inoculation. ARILVAX was significantly less reactogenic than YF-VAX, possibly because of the higher dose of virus in YF-VAX.
There was no difference between the ARILVAX and YF-VAX treatment groups in the incidence of asthenia, headache, malaise, myalgia, fever, and chills, reported by 10% to 30% of the participants (Table 3) . Although this was not a placebo-controlled study, the differences in AE reporting between immune and nonimmune individuals (see Table 7 ), the temporal relationship of AEs to vaccination, and the association of similar events with vaccination in previous trials 3, [26] [27] [28] [29] indicate causal relationships. These AEs as well as the mild decreases in granulocytes and platelets (Table 8) , are probably related to cytokine responses to acute infection with the vaccine virus. Increases in serum interferon-␣, 30 lymphocyte 2Ј5Ј-oligoadenylate synthetase, 31 and acute-phase reactants (neopterin, ␤ 2 microglobulin 32 ) and tumor necrosis factor-␣ 33 occur between 2 and 8 days after YF vaccination. A recent analysis of the VAERS database in the United States found the incidence of severe (but not mild) AEs to be significantly higher in elderly compared with younger individuals. In our study, elderly participants reported significantly fewer local and systemic AEs than younger individuals (Table 6 ). Two possible explanations may be suggested: (1) Elderly individuals in clinical research protocols may be more tolerant of mild adverse experiences and less likely to complain or (2) there may be a decreased innate immune response and cytokine-mediated syndrome in persons of advanced age. There was no relationship between age and antibody response in our study (data not shown).
The demand for additional sources of YF vaccines has increased, in concert with a resurgence of disease in incidence in endemic countries and an increase in travel to these regions. As shown in this study, ARILVAX and YF-VAX are both safe and effective vaccines, with equivalent immunogenicity. ARILVAX is associated with a lower incidence of local adverse reactions. Host-specific factors, including gender, race, and smoking, appear to influence the antibody response to YF vaccines, although the mechanisms underlying these effects remain uncertain.
